OBJECTIVE: To compare regimens consisting of either efavirenz or nevirapine and two or more nucleoside reverse transcriptase inhibitors (NRTIs) among HIV-infected, antiretroviral-naive, and AIDS-free individuals with respect to clinical, immunologic, and virologic outcomes. DESIGN: Prospective studies of HIV-infected individuals in Europe and the US included in the HIV-CAUSAL Collaboration. METHODS: Antiretroviral therapy-naive and AIDS-free individuals were followed from the time they started an NRTI, efavirenz or nevirapine, classified as following one or both types of regimens at baseline, and censored when they started an ineligible drug or at 6 months if their regimen was not yet complete. We estimated the 'intention-to-treat' effect for nevirapine versus efavirenz regimens on clinical, immunologic, and virologic outcomes. Our models included baseline covariates and adjusted for potential bias introduced by censoring via inverse probability weighting. RESULTS: A total of 15 336 individuals initiated an efavirenz regimen (274 deaths, 774 AIDS-defining illnesses) and 8129 individuals initiated a nevirapine regimen (203 deaths, 441 AIDS-defining illnesses). The intention-to-treat hazard ratios [95% confidence interval (CI)] for nevirapine versus efavirenz regimens were 1.59 (1.27, 1.98) for death and 1.28 (1.09, 1.50) for AIDS-defining illness. Individuals on nevirapine regimens experienced a smaller 12-month increase in CD4 cell count by 11.49 cells/μl and were 52% more likely to have virologic failure at 12 months as those on efavirenz regimens. CONCLUSIONS: Our intention-to-treat estimates are consistent with a lower mortality, a lower incidence of AIDS-defining illness, a larger 12-month increase in CD4 cell count, and a smaller risk of virologic failure at 12 months for efavirenz compared with nevirapine.
OBJECTIVE: To compare regimens consisting of either efavirenz or nevirapine and two or more nucleoside reverse transcriptase inhibitors (NRTIs) among HIV-infected, antiretroviral-naive, and AIDS-free individuals with respect to clinical, immunologic, and virologic outcomes. DESIGN: Prospective studies of HIV-infected individuals in Europe and the US included in the HIV-CAUSAL Collaboration. METHODS: Antiretroviral therapy-naive and AIDS-free individuals were followed from the time they started an NRTI, efavirenz or nevirapine, classified as following one or both types of regimens at baseline, and censored when they started an ineligible drug or at 6 months if their regimen was not yet complete. We estimated the 'intention-to-treat' effect for nevirapine versus efavirenz regimens on clinical, immunologic, and virologic outcomes. Our models included baseline covariates and adjusted for potential bias introduced by censoring via inverse probability weighting. RESULTS: A total of 15 336 individuals initiated an efavirenz regimen (274 deaths, 774 AIDS-defining illnesses) and 8129 individuals initiated a nevirapine regimen (203 deaths, 441 AIDS-defining illnesses). The intention-to-treat hazard ratios [95% confidence interval (CI)] for nevirapine versus efavirenz regimens were 1.59 (1.27, 1.98) for death and 1.28 (1.09, 1.50) for AIDS-defining illness. Individuals on nevirapine regimens experienced a smaller 12-month increase in CD4 cell count by 11.49 cells/μl and were 52% more likely to have virologic failure at 12 months as those on efavirenz regimens. CONCLUSIONS: Our intention-to-treat estimates are consistent with a lower mortality, a lower incidence of AIDS-defining illness, a larger 12-month increase in CD4 cell count, and a smaller risk of virologic failure at 12 months for efavirenz compared with nevirapine.
Authors: Lauren E Cain; James M Robins; Emilie Lanoy; Roger Logan; Dominique Costagliola; Miguel A Hernán Journal: Int J Biostat Date: 2010 Impact factor: 0.968
Authors: Martin Hartmann; Steffen Witte; Jürgen Brust; Dieter Schuster; Franz Mosthaf; Maria Procaccianti; Joerg Andres Rump; Hartwig Klinker; Detlef Petzoldt Journal: Int J STD AIDS Date: 2005-06 Impact factor: 1.359
Authors: B G Gazzard; Jane Anderson; Abdel Babiker; Marta Boffito; Gary Brook; Gary Brough; Duncan Churchill; Ben Cromarty; Satyajit Das; Martin Fisher; Andrew Freedman; Anna Maria Geretti; Margaret Johnson; Saye Khoo; Clifford Leen; Devaki Nair; Barry Peters; Andrew Phillips; Deenan Pillay; Anton Pozniak; John Walsh; Ed Wilkins; Ian Williams; Matthew Williams; Mike Youle Journal: HIV Med Date: 2008-10 Impact factor: 3.180
Authors: A N Phillips; C Pradier; A Lazzarin; B Clotet; F D Goebel; P Hermans; F Antunes; B Ledergerber; O Kirk; J D Lundgren Journal: AIDS Date: 2001-12-07 Impact factor: 4.177
Authors: Marlene Smurzynski; Kunling Wu; Jeffrey T Schouten; Judith J Lok; Ronald J Bosch; Babafemi Taiwo; Victoria Anne Johnson; Ann C Collier Journal: AIDS Date: 2013-07-31 Impact factor: 4.177
Authors: Lauren E Cain; Andrew Phillips; Ashley Olson; Caroline Sabin; Sophie Jose; Amy Justice; Janet Tate; Roger Logan; James M Robins; Jonathan A C Sterne; Ard van Sighem; Peter Reiss; James Young; Jan Fehr; Giota Touloumi; Vasilis Paparizos; Anna Esteve; Jordi Casabona; Susana Monge; Santiago Moreno; Rémonie Seng; Laurence Meyer; Santiago Pérez-Hoyos; Roberto Muga; François Dabis; Marie-Anne Vandenhende; Sophie Abgrall; Dominique Costagliola; Miguel A Hernán Journal: Clin Infect Dis Date: 2015-01-06 Impact factor: 9.079
Authors: Kate Shearer; Alana T Brennan; Mhairi Maskew; Lawrence Long; Rebecca Berhanu; Ian Sanne; Matthew P Fox Journal: J Int AIDS Soc Date: 2014-10-22 Impact factor: 5.396
Authors: Janneke H van Dijk; Catherine G Sutcliffe; Francis Hamangaba; Christopher Bositis; Douglas C Watson; William J Moss Journal: PLoS One Date: 2013-01-25 Impact factor: 3.240
Authors: Juan Manuel De La Hoz; Laura Bolaño; Oriana Cárdenas; Robertulio González; José Sabbag; Lucy Palacio; Luz Marina Alonso; Homero San-Juan-Vergara; Guillermo Cervantes-Acosta Journal: Colomb Med (Cali) Date: 2014-12-30
Authors: Barbara Castelnuovo; Agnes Kiragga; Frank Mubiru; Andrew Kambugu; Moses Kamya; Steven J Reynolds Journal: J Int AIDS Soc Date: 2016-06-17 Impact factor: 5.396